Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Rimonabant—a new hope in the treatment of obesity?

Nature Clinical Practice Endocrinology & Metabolism volume 2, pages 370–371 (2006)Cite this article

boxed-textDesprés J-P et al. (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121–2134

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Padwal R et al. (2003) Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27: 1437–1446

    Article  CAS  Google Scholar 

  2. Wirth A and Krause J (2001) Long-term weight loss with sibutramine. A randomized controlled trial. JAMA 286: 1331–1339

    Article  CAS  Google Scholar 

  3. Pi-Sunyer FX et al. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 295: 761–775

    Article  CAS  Google Scholar 

  4. Witkin JM et al. (2005) A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci 26: 609–617

    Article  CAS  Google Scholar 

  5. Cota D et al. (2006) Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Brain Res Rev 51: 85–107

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Postdoctoral Research Associate in the Department of Obstetrics and Gynecology and Reproductive Sciences,

    Alfonso Abizaid & Tamas L Horvath

  2. Chair in the Section of Comparative Medicine and Professor of Comparative Medicine, Obstetrics and Gynecology and Neurobiology at Yale School of Medicine, New Haven, CT, USA

    Alfonso Abizaid & Tamas L Horvath

Authors
  1. Alfonso Abizaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tamas L Horvath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tamas L Horvath.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abizaid, A., Horvath, T. Rimonabant—a new hope in the treatment of obesity?. Nat Rev Endocrinol 2, 370–371 (2006). https://doi.org/10.1038/ncpendmet0218

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0218

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing